International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 5, Issue 2, pp: (471-476), Month: October 2017 - March 2018, Available at: www.researchpublish.com

Consequences and Improvement Strategies for Antibiotic Use in ICU

[1]Dr. Nada AlGhawi, [2]Dr. Fatimah AlGhawi

[1]BSc, MD, [2]BSc, MD

Abstract: **This review discusses the use strategies, the importance of microbiology knowledge and how in-ICU antibiotic therapy could possibly be optimized and rationalized. A search of literature through databases; MIDLINE, and EMBASE was conducted to identified related articles to our concerned topic (improvement strategies for antibiotic use in ICU) we were published up to November 2017. Bacterial resistance is an expanding and global issue, as are high death rates in septic patients treated inadequately. Clinicians practicing in intensive care units must develop and promote strategies for better employing antimicrobial treatment. One of the most successful strategies will be multidisciplinary, involving collaboration from the pharmacy, infection control, nursing team, treating doctors, and infectious disease consultants. Such programs must additionally focus both on promoting infection control practices and employing rational antibiotic usage targeted at minimizing future emergence of resistance.**

Keywords: **strategies, improvement strategies, antibiotic.**

1. INTRODUCTION

Ideal antibiotic usage is critical in the critical care setup, especially in an age of climbing antibiotic resistance and lack of new antimicrobial development [1], [2]. Research study results suggest that 30% to 60% of prescription antibiotics suggested in ICUs are unnecessary, unacceptable, or suboptimal [3], [4].Overprescribing and misprescribing antibiotics are undoubtedly adding to the growing challenges presented by antibiotic-resistant bacteria, and epidemiological research studies have plainly shown direct relationships between antibiotic intake and the emergence and dissemination of resistant pressures in health centers and ICUs [4], [6].As specified by the Society of Healthcare Epidemiology of America and Infectious Diseases Society of America (IDSA) Joint Committee on the Prevention of Antimicrobial Resistance in healthcare facilities, 'stewardship of antimicrobials is a proper descriptor of associated activities that aid maximize antimicrobial therapy, ensuring the finest scientific outcome for the patient while decreasing the danger of subsequent growth of antimicrobial resistance' [5].Therefore, in-ICU antibiotic stewardship incorporates fast recognition of patients with microbial infections, better empirical therapy selection, making use of pharmacokinetic-pharmacodynamic (PK-PD) characteristics to enhance antibiotic application and administration techniques, de-escalation once society results appeared, shortening treatment duration, and minimizing the numbers of patients treated unnecessarily.

Sadly, improving in-ICU antibiotic usage is especially difficult for three main reasons: infection intensity commonly averts taking out or delaying antibiotics, the complex decision-making procedure regularly entails medical professionals with restricted proficiency, and it is difficult to guarantee disease-long connection of care by the same medical team 24 hours a day, 7 days a week.

This review discusses the use strategies, the importance of microbiology knowledge and how in-ICU antibiotic therapy could possibly be optimized and rationalized.

2. METHODOLOGY

A search of literature through databases; MIDLINE, and EMBASE was conducted to identified related articles to our concerned topic (improvement strategies for antibiotic use in ICU) we were published up to November 2017, Following Mesh terms were used in our search through the MIDLINE; ICU, Antibiotics, and complications, Combined with management, and improvement. We limited our search to English language published articles with human subject.

3. DISCUSSION

- **Rapid identification of intensive care unit patients with bacterial infections:**

Many released observational data recommend that the moment to ideal antibiotic administration is a major outcome determinant for ICU patients with severe bacterial infections. Without a doubt, each hr of delay in providing efficient anti-biotics for septic shock is associated with measurably boosted mortality [8], [7].Thus, as highly recommended by all guidelines [9], getting biological specimens ought to not delay prompt antibiotic management to patients with severe sepsis or septic shock.

However, owing to technical problems, the unsafe results of poor therapy are not approved by all [10].Since in-ICU indications and symptoms of infection as a result of non-infectious reasons prevail, hurrying to prescribe antibiotics could imply that many clean patients obtain unneeded treatment. In a quasi-experimental, before-and-after, observational cohort research study of patients confessed to the University of Virginia surgical ICU, Hranjec and associates [11] proposed that postponing prescription antibiotics for hemodynamically secure patients with presumed infections (35% pneumonia) up until they were objectively recorded would certainly not get worse mortality. Notably, that conventional strategy was linked with reduced all-cause mortality, even more initially proper therapy, and shorter mean therapy duration than the aggressive approach. Therefore, for clinically stable patients, that method might attain far better antibiotic use without influencing prognosis. Getting samplings for suitable cultures before antibiotic administration is necessary to confirm infection, recognize responsible pathogens, and allow treatment de-escalation in response to susceptibility profiles.

The mistake of standard methods to identify hospital-acquired infections (HAIs) and the impossibility of those techniques to avoid antibiotic overprescription led some investigators to hypothesize that using biological markers - as an example, C-reactive healthy protein, soluble-triggering receptor shared on myeloid cells-1, or procalcitonin (PCT) - might better recognize true microbial infections and facilitate therapeutic choices. However, although PCT is a good pen of community-acquired infections (CAIs), it does not seem to be for HAIs [12].Without a doubt, blood PCT concentrations can increase in different non-septic problems: significant trauma, surgery, acute respiratory distress syndrome, multiorgan failure, post-transplantation denial, cardiogenic shock, severe burns, warm stroke, and so on. Therefore, high PCT focus the day sepsis is thought are non-contributory because increases that are attributable to a prior non-infectious condition or energetic infection could not be identified. Furthermore, PCT could continue to be low in some microbiologically shown bacterial infections, either due to the fact that the infection stays had in a tissue compartment that can manufacture PCT in your area without systemic release, consequently clarifying the reduced serum level in spite of true infection, or due to a 24- to 48-hour lag time in infection beginning to peak PCT launch. Hence, intensivists are appropriately unwilling to rely solely on biological pens when severe infection is presumed [12].

- **Selection of initial antibiotic therapy:**

Owing to the emergence of multiresistant Gram-negative bacilli (GNB) (for instance, Pseudomonas aeruginosa, extended-spectrum β-lactamase-producing Enterobacteriaceae, and carbapenemase-producing Klebsiella pneumoniae) and the enhancing role of Gram-positive bacteria (like methicillin-resistant Staphylococcus aureus, or MRSA), empirical broad-spectrum antibiotics are warranted for the majority of ICU patients with clinically suspected HAIs [8].Regimen selection need to be based on neighborhood antimicrobial sensitivity patterns and expected adverse effects while taking into consideration the anti-biotics got within the preceding 2 weeks and striving whenever possible not to use the same courses [13].Having current and often updated knowledge of neighborhood bacteriological public health increases the probability of suggesting appropriate first prescription antibiotics. Whether security cultures might better improve empirical treatment option for ICU patients with presumed hospital-acquired pneumonia (HAP) is still disputed but definitely ought to be considered when difficult-to-treat microbes are plentiful, making first choices specifically dangerous [14].Observational research study results verified that preliminary routines combining a broad-spectrum β-lactam and an aminoglycoside increased the percentage of suitably treated patients compared to monotherapy or a combination of β-lactam and fluoroquinolone [15].Only patients with gently or reasonably extreme, early-onset infections and no details threat aspects (as an example, long term hospitalization, immunosuppression, or recent extended anti-biotics or a mix of these) can receive a reasonably narrow-spectrum medicine, like a non-pseudomonal third-generation cephalosporin.

For ICU patients confessed with health care-associated or community-onset infections or CAIs, more restrictions for antimicrobial treatment choice are definitely possible. For instance, it is increasingly recognized that using current criteria for health care-associated pneumonia - hospitalization for at the very least 2 days during the preceding 90 days, residence in a nursing home or extended-care center, home intravenous (prescription antibiotics or chemotherapy) treatment, and

chronic dialysis or residence wound care (or both) throughout the preceding 30 days - as indicators for broad-spectrum prescription antibiotics could result in overtreatment of lots of patients with pneumonia. To address this conceptual limitation, private investigators established several risk-assessment designs that refine those standards [16].Offered information recommend that the occurrence of pathogens immune to the normal in-patient IDSA-American Thoracic Society guideline-recommended antibiotic program (that is, a non-pseudomonal cephalosporin and a macrolide) is usually not considerably raised unless two or more threat variables are existing, with prior antibiotic use or hospitalization and inadequate useful status being extra vital predictors of resistant bacteria than nursing-home home alone [16].Utilizing such an algorithm could lead to fewer pneumonia patients needlessly obtaining broad-spectrum prescription antibiotics.

- **Antimicrobial optimization strategies:**

Guidelines/protocols:

Antibiotic management guidelines/protocols established in your area or by nationwide societies potentially prevent unneeded antibiotic administration and boost healing performance. However, also strong guidelines/protocols could not convert into extensively approved treatment formulas. Some deviation from guidelines/protocols is expected due to the fact that medical decision-making ought to be led by an individual patient's attributes and the judgement and experience of the caregivers. Locally created standards therefore usually have the ideal chance of being accepted by neighborhood healthcare providers and hence of being carried out [17].

The possible benefits of guidelines/protocols have been well shown by the Latter Day Saints Hospital in Salt Lake City, Utah, where a digital system guides antibiotic management. The system immediately identifies and lessens negative medication impacts as a result of anti-biotics [18] and has minimized poor administration contrasted with medical professional suggesting patterns.The system has also been related to secure antibiotic susceptibility patterns with time, both for Gram-positive and Gram-negative germs [19].It has most recently been revealed to substantially lower orders for medicines to which patients were sensitive, the number of negative occasions brought on by anti-biotics, and the total variety of antibiotic doses recommended, in addition to the medical costs related to antimicrobial agents.

Non-automated or partially automated systems, normally driven by hospital-based top quality enhancement groups, have shown comparable outcomes [20].Bailey et alia randomized patients to make sure that pharmacologists gotten in touch with a few of their doctors with recommendations for discontinuing intravenous antibiotics [21].The pharmacologists' treatment dramatically minimized antibiotic dosages and indicate antibiotic costs, but was connected with enhanced labour costs. Likewise, Leibovici et alia created a problem-oriented decision support system that substantially reduced the indiscreet or insufficient management of anti-biotics, particularly in patients infected with multiresistant Gram-negative isolates, enterococci, and S. aureus [22].As modern technology, such as handheld computer systems and portable communication tools, comes to be extensively readily available there is more chance to influence treatment methods.

Two groups of detectives just recently showed making use of protocols/guidelines for the management of ventilator-associated pneumonia (VAP). Singh et al used a scoring system to identify patients with presumed VAP who might be treated with 3 days of anti-biotics instead of the standard method of 10-21 days [23].Patients getting the much shorter program had similar clinical results to the patients obtaining the longer course however with less subsequent superinfections credited to antibiotic-resistant microorganisms. Ibrahim et al utilized a pharmacist-directed method in intensive care units to minimize the administration of antibiotics for presumed VAP to 8.1 ± 5.1 days from 14.8 ± 8.1 days ($P < 0.001$) [24].

Scheduled changes in antibiotic:

To combat an episode of infection from extended spectrum B-lactamase-producing Klebsiella, Rahal et alintroduced an antibiotic standard into their hospital that significantly restricted using cephalosporins [25] Using cephalosporins was reduced by 80.1%, which was come with by a 44.0% reduction in infection and emigration with extensive spectrum B-lactamase-producing Klebsiella. At the very same time, nevertheless, making use of imipenem boosted by 140.6% and was associated with a 68.7% rise in the occurrence of imipenem-resistant P. aeruginosa.

Kollef et al analyzed the influence of a scheduled modification in antibiotic on the incidence of nosocomial infections amongst patients undergoing cardiac surgery [26] In the 6 months preceding the surgery, a third-generation cephalosporin (ceftazidime) was made use of for the therapy of Gram-negative microbial infections. In the 6 months after the surgery, a fluoroquinolone (ciprofloxacin) was used. All of a sudden, the overall incidence of VAP was significantly decreased in the 6 months after the surgery compared with the 6 months in the past, largely due to a considerable reduction in the

incidence of VAP credited to antibiotic-resistant Gram-negative microorganisms. A reduced incidence of antibiotic-resistant Gram-negative bacteraemia was in a similar way observed in the 6 months after the surgery. This experience was complied with by a series of arranged antibiotic modifications for the treatment of presumed Gram-negative microbial infections among patients admitted to the medical and surgical critical care unit. In general, the prescription of adequate antimicrobial treatment was statistically enhanced for Gram-negative bacterial infections. Nevertheless, the long-lasting efficiency of a limited variety of arranged antibiotic modifications is unidentified owing to the capacity for raised emergence of resistance to the newly selected antibiotic courses [25].

Combining antibiotic therapy:

The use of combination antimicrobial therapy has been proposed as a method to reduce the introduction of bacterial resistance, as has been utilized for Mycobacterium tuberculosis [26].However, no persuading information exist to confirm this hypothesis for nosocomial pneumonia [27].Definitive data that mix antibiotic therapy for nosocomial blood stream infections avoids the succeeding emergence of antibiotic resistance is similarly lacking [28] Nevertheless, there is some indirect proof that the use of mix antimicrobial therapy may be beneficial.

In the County of Northern Jutland, Denmark, all bacter-aemia were analysed when it come to antibiotic resistance over a 14-year period (1981-1995) [29].An overall of 8840 isolates from 7938 episodes of bacteraemia were identified. The degree of resistance to third-generation cephalosporins, carbapenems, aminoglycosides, and fluoroquinolones amongst Enterobacteriaceae was reduced (<1%). The suggested program for empirical antibiotic therapy in this area is a combination of penicillin G or ampi-cillin and an aminoglycoside, which gave an overall protection of 94%. This experience recommends that combination therapy with slim range representatives over extended amount of time may help suppress resistance to wide spectrum anti-biotics, yet still supply effective treatment of serious infections to include bacteraemia.

Antibiotic rotation:

The principle of antibiotic class cycling has been supported as a potential technique for reducing the emergence of antimicrobial resistance [30].Theoretically, a class of anti-biotics or a details antibiotic medicine is withdrawn from use for a defined amount of time and reestablished at a later time in an effort to restrict microbial resistance to the cycled antimicrobial agents [31].Nonetheless, limited clinical data is currently available that has taken a look at the problem of antibiotic course modifications or cycling [32].

Gerding et al reviewed cycling of aminoglycosides during 10 years at the Minneapolis Veterans Affairs Medical Center, cycling amikacin and gentamicin [33].Resistance to gentamicin had actually become a scientific issue restricting making use of that specific aminoglycoside at this medical facility. Utilizing cycle times of 12-51 months, these private investigators located considerably minimized resistance to gentamicin when amikacin was utilized, but a return of resistance with the rapid reintroduction of gentamicin. This was complied with by more progressive reintroduction of gentamicin a 2nd time, without enhanced degrees of resistance repeating. This experience suggested that the cycling of antibiotics within the exact same medicine class, in some circumstances, might be a reliable approach for curbing antimicrobial resistance.

4. CONCLUSION

Bacterial resistance is an expanding and global issue, as are high death rates in septic patients treated inadequately. Clinicians practicing in intensive care units must develop and promote strategies for better employing antimicrobial treatment. One of the most successful strategies will be multidisciplinary, involving collaboration from the pharmacy, infection control, nursing team, treating doctors, and infectious disease consultants. Such programs must additionally focus both on promoting infection control practices and employing rational antibiotic usage targeted at minimizing future emergence of resistance.

REFERENCES

[1] Arnold HM, Micek ST, Skrupky LP, Kollef MH. Antibiotic stewardship in the intensive care unit. Semin Respir Crit Care Med. 2011;32:215–227. doi: 10.1055/s-0031-1275534.

[2] Leuthner KD, Doern GV. Antimicrobial stewardship programs. J Clin Microbiol. 2013;51:3916–3920. doi: 10.1128/JCM.01751-13.

[3] Bergmans DC, Bonten MJ, Gaillard CA, van Tiel FH, van der Geest S, de Leeuw PW, Stobberingh EE. Indications for antibiotic use in ICU patients: a one-year prospective surveillance. J Antimicrob Chemother. 1997;39:527–535. doi: 10.1093/jac/39.4.527.

[4] Kollef MH, Fraser VJ. Antibiotic resistance in the intensive care unit. Ann Intern Med. 2001;134:298–314. doi: 10.7326/0003-4819-134-4-200102200-00014.

[5] Shlaes DM, Gerding DN, John JF, Jr, Craig WA, Bornstein DL, Duncan RA, Eckman MR, Farrer WE, Greene WH, Lorian V, Levy S, McGowan JE, Jr, Paul SM, Ruskin J, Tenover FC, Watanakunakorn C. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America joint committee on the prevention of antimicrobial resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis. 1997;25:584–599. doi: 10.1086/513766.

[6] Landman D, Quale JM, Mayorga D, Adedeji A, Vangala K, Ravishankar J, Flores C, Brooks S. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch Intern Med. 2002;162:1515–1520. doi: 10.1001/archinte.162.13.1515.

[7] Kollef MH. Optimizing antibiotic therapy in the intensive care unit setting. Crit Care. 2001;5:189–195. doi: 10.1186/cc1022.

[8] Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D, Laporta D, Lapinsky S, Ellis P, Mirzanejad Y, Martinka G, Keenan S, Wood G, Arabi Y, Feinstein D, Dodek P, Kravetsky L, Doucette S. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med. 2010;38:1773–1785. doi: 10.1097/CCM.0b013e3181eb3ccd.

[9] Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41:580–637.

[10] Amaral AC, Holder MW. Timing of antimicrobial therapy after identification of ventilator-associated condition is not associated with mortality in patients with ventilator-associated pneumonia: a cohort study. PLoS One. 2014;9:e97575. doi: 10.1371/journal.pone.0097575.

[11] Hranjec T, Rosenberger LH, Swenson B, Metzger R, Flohr TR, Politano AD, Riccio LM, Popovsky KA, Sawyer RG. Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive-care-unit-acquired infection: a quasi-experimental, before and after observational cohort study. Lancet Infect Dis. 2012;12:774–780. doi: 10.1016/S1473-3099(12)70151-2.

[12] Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, Schortgen F, Lasocki S, Veber B, Dehoux M, Bernard M, Pasquet B, Regnier B, Brun-Buisson C, Chastre J, Wolff M. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (prorata trial): a multicentre randomised controlled trial. Lancet. 2010;375:463–474. doi: 10.1016/S0140-6736(09)61879-1.

[13] Luyt CE, Aubry A, Lu Q, Micaelo M, Brechot N, Brossier F, Brisson H, Rouby JJ, Trouillet JL, Combes A, Jarlier V, Chastre J. Imipenem, meropenem, or doripenem to treat patients with pseudomonas aeruginosa ventilator-associated pneumonia. Antimicrob Agents Chemother. 2014;58:1372–1380. doi: 10.1128/AAC.02109-13.

[14] Brusselaers N, Labeau S, Vogelaers D, Blot S. Value of lower respiratory tract surveillance cultures to predict bacterial pathogens in ventilator-associated pneumonia: systematic review and diagnostic test accuracy meta-analysis. Intensive Care Med. 2013;39:365–375. doi: 10.1007/s00134-012-2759-x.

[15] Martinez JA, Cobos-Trigueros N, Soriano A, Almela M, Ortega M, Marco F, Pitart C, Sterzik H, Lopez J, Mensa J. Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. Antimicrob Agents Chemother. 2010;54:3590–3596. doi: 10.1128/AAC.00115-10.

[16] Clerc O, Prod'hom G, Vogne C, Bizzini A, Calandra T, Greub G. Impact of matrix-assisted laser desorption ionization time-of-flight mass spectrometry on the clinical management of patients with gram-negative bacteremia: a prospective observational study. Clin Infect Dis. 2013;56:1101–1107. doi: 10.1093/cid/cis1204.

[17] Clemmer TP, Spuhler VJ, Berwick DM, Nolan TW. Cooperation: the foundation of improvement. Ann Intern Med. 1998;128:1004–1009.

[18] Pestotnik SL, Classen DC, Evans RS, Stevens LE, Burke JP. Prospective surveillance of imipenem/cilastin use and associated seizures using a hospital information system. Ann Pharmacother. 1993;27:497–501.

[19] Pestotnik SL, Classen DC, Evans RS, Burke JP. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med. 1996;124:884–890.

[20] Carr JR, Fitzpatrick P, Izzo JL, Cumbo TJ, Birmingham MC, Adelman MH, Paladino JA, Hanson SC, Schentag JJ. Changing the infection control paradigm from off-line to real time: the experience at Millard Fillmore Health System. Infect Control Hosp Epidemiol. 1997;18:255–259.

[21] Bailey TC, Ritchie DJ, McMullin ST, Kahn M, Reichley RM, Casabar E, Shannon W, Dunagan WC. A randomized, prospective evaluation of an interventional program to discontinue intravenous antibiotics at two tertiary care teaching institutions. Pharmacotherapy. 1997;17:277–281.

[22] Leibovici L, Gitelman V, Yehezkelli Y, Poznanski O, Milo G, Paul M. Improving empirical antibiotic treatment: prospective, non-intervention testing of a decision support system. J Intern Med. 1997;242:395–400.

[23] Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med. 2000;162:505–511.

[24] Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med. 2001;29:1109–1115.

[25] Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, Mariano N, Marks S, Burns JM, Dominick D, Lim M. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA. 1998;280:1233–1237.

[26] Kollef MH, Vlasnik J, Sharpless L, Pasque C, Murphy D, Fraser VJ. Scheduled rotation of antibiotic classes. A strategy to decrease the incidence of ventilator-associated pneumonia due to antibiotic-resistant gram-negative bacteria. Am J Respir Crit Care Med. 1997;156:1040–1048.

[27] Yates RR. New intervention strategies for reducing antibiotic resitance. Chest. 1999;115:24S–27S.

[28] Bergogne-Berezin E. Treatment and prevention of nosocomial pneumonia. Chest. 1995;108:26S–34S.

[29] Siegman-Igra Y, Ravona R, Primerman H, Giladi M. Pseudomonas aeruginosa bacteremia: an analysis of 123 episodes, with particular emphasis on the effect of antibiotic therapy. Int J Infect Dis. 1998;2:211–215.

[30] Sanders WE, Jr, Sanders CC. Circumventing antibiotic resistance in specialized hospital units. Clin Microbiol Infect. 1997;3:272–273.

[31] Niederman MS. Is "crop rotation" of antibiotics the solution to a "resistant" problem in the ICU? Am J Respir Crit. 1997;156:1029–1031.

[32] Kollef MH. Is there a role for antibiotic cycling in the intensive care unit? Crit Care Med. 2001;29:N135–N142.

[33] Gerding DN, Larson TA, Hughes RA, Weiler M, Shanholtzer C, Peterson LR. Aminoglycoside resistance and aminoglycoside usage: Ten years of experience in one hospital. Antimicrob Agents Chemother. 1991;35:1284–1290.